Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms

Trial Profile

Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Givinostat (Primary)
  • Indications Myeloproliferative disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Italfarmaco
  • Most Recent Events

    • 06 Dec 2016 Preliminary results (n=12 patients in part A) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Feb 2016 Planned End Date changed from 1 Mar 2019 to 1 Dec 2020 as reported by ClinicalTrials.gov record.
    • 03 Feb 2016 Planned number of patients changed from 60 to 90 ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top